| David Babbel, DO | |
|
315 E Elm St, Caldwell, ID 83605-4857 | |
| (208) 302-7100 | |
| (208) 302-7155 |
| Full Name | David Babbel |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 315 E Elm St, Caldwell, Idaho |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861434961 | NPI | - | NPPES |
| 806057300 | Medicaid | ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | O265 (Idaho) | Primary |
| Entity Name | Saint Alphonsus Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649357716 PECOS PAC ID: 3476462359 Enrollment ID: O20040204001036 |
News Archive
IRIN reports on women's efforts to curb population growth in Madagascar, "one of 12 developing countries receiving support to improve access to contraceptives through the U.N. Population Fund's (UNFPA) Global Programme to Enhance Reproductive Health Commodity Security."
If the placenta is not functioning properly it could be a potential danger to the health of the mother and fetus. Abnormalities can lead to conditions such as preeclampsia, which is maternal high blood pressure, stillbirth or the need for a pre-term delivery.
Kylene Kehn-Hall, Associate Professor/Associate Director, School of Systems Biology, National Center for Biodefense and Infectious Diseases, is working to rapidly test and deploy a universal virus enrichment tool that can be used to enhance the detection of SARS-CoV-2 (COVID-19) for any type of diagnostic assay under development, thereby reducing false negatives and the risk of worldwide pandemic.
Alexza Pharmaceuticals, Inc. today announced that it has updated and amended its ADASUVE (Staccato loxapine) commercial partnerships with Grupo Ferrer Internacional, S.A. and Teva Pharmaceutical Industries Ltd. Ferrer is Alexza's commercial partner for ADASUVE in the European Union, Latin America, the Commonwealth of Independent States and other countries in Europe.
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Babbel, DO 3340 E Goldstone Way, Meridian, ID 83642-1026 Ph: (208) 302-7100 | David Babbel, DO 315 E Elm St, Caldwell, ID 83605-4857 Ph: (208) 302-7100 |
News Archive
IRIN reports on women's efforts to curb population growth in Madagascar, "one of 12 developing countries receiving support to improve access to contraceptives through the U.N. Population Fund's (UNFPA) Global Programme to Enhance Reproductive Health Commodity Security."
If the placenta is not functioning properly it could be a potential danger to the health of the mother and fetus. Abnormalities can lead to conditions such as preeclampsia, which is maternal high blood pressure, stillbirth or the need for a pre-term delivery.
Kylene Kehn-Hall, Associate Professor/Associate Director, School of Systems Biology, National Center for Biodefense and Infectious Diseases, is working to rapidly test and deploy a universal virus enrichment tool that can be used to enhance the detection of SARS-CoV-2 (COVID-19) for any type of diagnostic assay under development, thereby reducing false negatives and the risk of worldwide pandemic.
Alexza Pharmaceuticals, Inc. today announced that it has updated and amended its ADASUVE (Staccato loxapine) commercial partnerships with Grupo Ferrer Internacional, S.A. and Teva Pharmaceutical Industries Ltd. Ferrer is Alexza's commercial partner for ADASUVE in the European Union, Latin America, the Commonwealth of Independent States and other countries in Europe.
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.
› Verified 2 days ago
Jee Hur, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 315 E Elm Street, Ste 100, Caldwell, ID 83605 Phone: 208-459-7415 Fax: 208-453-3307 | |
Natasha Miller, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 315 E Elm, Ste 100, Caldwell, ID 83605 Phone: 208-459-7415 Fax: 208-453-3307 | |
Amanda Lee, Pediatrics Medicare: Medicare Enrolled Practice Location: 1620 S Kimball Ave, Caldwell, ID 83605 Phone: 208-505-2950 | |
Merle L. Keller Iii, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 315 E. Elm Ste 100, Caldwell, ID 83605 Phone: 208-302-7100 Fax: 208-302-7155 | |
Matthew S Brown, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 315 E Elm St Ste 100, Caldwell, ID 83605 Phone: 208-302-7100 Fax: 208-302-7189 | |
Timothy Curtis Borup, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 315 E Elm St Ste 100, Caldwell, ID 83605 Phone: 208-302-7100 Fax: 208-302-7155 |